Myo-inositol vs NAD+ boosters

Our assessment

Myo-inositol and NAD+ boosters operate on fundamentally different biological pathways. Myo-inositol directly targets glucose metabolism and insulin sensitivity by improving how your cells take up glucose and respond to insulin signaling NIH ODS ↗. NAD+ boosters, by contrast, focus on cellular longevity through autophagy activation — essentially promoting the cleanup and recycling of damaged cellular components NIH ODS ↗. Think of Myo-inositol as a metabolic fine-tuner for your blood sugar machinery, while NAD+ boosters act as a cellular housekeeping service that sweeps out the old to make room for the new.

How it works

Choose Myo-inositol when your primary concern is related to metabolic health — specifically conditions involving insulin resistance, such as polycystic ovary syndrome (PCOS) or prediabetes. The data shows it works by enhancing insulin signaling at the cellular level, which can help lower blood glucose and improve ovulation in PCOS NIH ODS ↗. Choose NAD+ boosters when your goal is to support healthy aging, cellular repair, or mitochondrial function. By ramping up autophagy, NAD+ boosters help your body clear out misfolded proteins and damaged organelles, a process that declines with age NIH ODS ↗.

Safety profile

Data not available for specific side effect reports from FDA data for either Myo-inositol or NAD+ boosters. Both are generally considered well-tolerated based on available information, but clinical data on long-term safety profiles at high doses is limited NIH ODS ↗. Because Myo-inositol directly affects glucose metabolism, individuals on diabetes medications should monitor blood sugar closely. NAD+ boosters, while promising for cellular health, lack extensive long-term human safety data NIH ODS ↗.

Our recommendation

Your choice depends entirely on your primary health target. If you are managing insulin resistance, PCOS, or metabolic syndrome, choose Myo-inositol — it directly addresses the root mechanism of glucose dysregulation. If your focus is on slowing biological aging, improving cellular repair, or supporting cognitive function in an aging brain, choose NAD+ boosters. The trade-off is clear: Myo-inositol offers targeted metabolic benefits with a narrower scope, while NAD+ boosters provide broader cellular support but with less direct evidence for specific disease states NIH ODS ↗.

Myo-inositol may be better if: Glucose metabolism / insulin sensitivity: Improves glucose uptake and insulin signaling

NAD+ boosters may be better if: Autophagy activation: Promotes cellular cleanup and recycling processes